RpL10 Antibody

What is RPL10 and why is it relevant to biological research?

RPL10 (ribosomal protein L10) is a 214 amino acid protein belonging to the universal ribosomal protein uL16 family. It functions as a critical component of the large ribosomal subunit (60S) and plays essential roles in ribosome assembly and protein translation processes . RPL10 is also known as "Large ribosomal subunit protein uL16" in scientific literature. The significance of RPL10 extends beyond its canonical role in ribosome function, as it has demonstrated important extra-ribosomal functions that implicate it in various cellular processes and disease states .

Research has shown that RPL10 is down-regulated during adipocyte, kidney, and heart differentiation, suggesting its involvement in developmental processes . More significantly, recent studies have revealed its potential role in cancer biology, particularly in pancreatic adenocarcinoma (PAAD) where post-translational modifications of RPL10, specifically ufmylation, appear to influence cancer cell stemness and proliferation . These diverse functions make RPL10 an important target for scientific investigation across multiple fields, from basic ribosome biology to cancer research.

What are the key technical specifications of commercially available RPL10 antibodies?

RPL10 antibodies are available as polyclonal or monoclonal formats, with rabbit polyclonal IgG being a common configuration. The typical molecular weight observed for RPL10 is approximately 25 kDa, which aligns with its calculated molecular weight . Most commercial antibodies target the full RPL10 protein or specific epitopes within its sequence, with some using RPL10 fusion proteins as immunogens .

These antibodies generally demonstrate reactivity across multiple species, with human, mouse, and rat samples being most commonly validated. Some antibodies also have predicted reactivity with other species such as pig, zebrafish, bovine, horse, sheep, rabbit, chicken, and Xenopus, though these require experimental verification . It's important to note that RPL10 shares approximately 98% amino acid sequence identity with RPL10L, meaning that RPL10 antibodies may recognize both proteins in experimental contexts .

How should RPL10 antibodies be stored and handled to maintain optimal activity?

Proper storage and handling of RPL10 antibodies are crucial for maintaining their specificity and activity. The recommended storage condition for most RPL10 antibodies is -20°C, where they typically remain stable for at least one year after shipment . The storage buffer generally consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps maintain antibody structure and prevent microbial contamination .

For antibodies in smaller volumes (e.g., 20μL), manufacturers may include 0.1% BSA in the formulation to help stabilize the protein . When handling these antibodies, it's important to minimize freeze-thaw cycles, as repeated freezing and thawing can lead to protein denaturation and reduced antibody performance. For antibodies stored at -20°C, aliquoting is generally unnecessary according to manufacturer guidelines, which simplifies laboratory handling processes . Always follow specific manufacturer recommendations, as formulations may vary slightly between suppliers.

What are the validated applications for RPL10 antibodies and their recommended dilutions?

RPL10 antibodies have been successfully employed across multiple experimental applications, with Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), and ELISA being the most commonly validated techniques . For optimal results in Western Blot applications, the recommended dilution range is typically between 1:1000 and 1:6000, which should be optimized based on the specific experimental system and detection method . For Immunohistochemistry applications, a dilution range of 1:50 to 1:500 is generally recommended .

Published literature demonstrates successful use of RPL10 antibodies in all these applications, with at least four publications utilizing Western Blot, one employing IHC, and one applying IF techniques . When performing immunohistochemistry, antigen retrieval methods significantly impact results, with most protocols suggesting TE buffer at pH 9.0 or alternatively citrate buffer at pH 6.0 . As with all antibody applications, it is advisable to titrate the antibody concentration in each specific testing system to achieve optimal results, as signal strength may vary depending on sample type and experimental conditions.

What positive controls and sample types have been validated for RPL10 antibody applications?

Several cell lines and tissue types have been validated as positive controls for RPL10 antibody applications. For Western Blot analysis, HeLa cells, COLO 320 cells, mouse brain tissue, and rat brain tissue have all demonstrated positive detection of RPL10 . These samples provide reliable positive controls when establishing or troubleshooting Western Blot protocols.

For Immunohistochemistry applications, mouse brain tissue and human liver tissue have been validated as positive controls . The effectiveness of RPL10 antibody detection in these tissues demonstrates its utility across different sample types and species. When working with new sample types not previously validated, researchers should include appropriate positive controls from this list alongside experimental samples to ensure proper antibody performance and accurate interpretation of results.

How can researchers validate the specificity of RPL10 antibodies in their experimental systems?

Three primary enhanced validation methods are recommended:

• siRNA knockdown: This approach evaluates the decrease in antibody staining intensity when the target protein is downregulated through siRNA. A significant reduction in signal compared to control samples confirms antibody specificity .

• Tagged GFP cell lines: This method compares antibody staining patterns with the localization of a GFP-tagged version of the target protein. Substantial overlap between antibody staining and GFP signal indicates specificity to the target protein .

• Independent antibodies: This validation approach compares staining patterns of two or more independent antibodies directed toward different epitopes on the same protein. Concordant staining patterns across different antibodies strongly support specificity .

These validation approaches should be considered essential steps when using RPL10 antibodies in critical research applications, particularly for publication-quality data or when exploring novel biological phenomena.

What role does RPL10 ufmylation play in cancer biology, particularly in pancreatic cancer?

Recent research has revealed that post-translational modification of RPL10 via ufmylation plays a significant role in pancreatic cancer biology. Ufmylation is a ubiquitin-like modification process that appears to enhance the stemness of pancreatic cancer cells, contributing to pancreatic adenocarcinoma (PAAD) development . Studies have demonstrated that RPL10 undergoes ufmylation in both pancreatic cancer patient tissues and cell lines, with the modification being mediated by the E3 ligase UFL1 at specific sites and subsequently cleaved by the enzyme UFSP2 .

Experimental evidence shows that the level of RPL10 ufmylation in PAAD tumor tissues is 2-3 fold higher than in adjacent normal tissues, indicating a strong association between this modification and cancer development . Mechanistically, the decrease of RPL10 ufmylation inhibits pancreatic cancer cell proliferation and stemness, with the degree of RPL10 ufmylation positively correlating with the expression of the transcription factor KLF4, a key regulator of cell stemness . Furthermore, mutagenesis of specific ufmylation sites in RPL10 has been shown to impede the proliferation and stemness of pancreatic cancer cells, highlighting the functional importance of this modification in cancer biology .

How has RPL10 been implicated in hematological malignancies?

Beyond its role in solid tumors, RPL10 has been implicated in hematological malignancies, particularly in acute T-lymphoblastic leukemia. Research has identified that approximately 9.8% of children with acute T-lymphoblastic leukemia harbor an R98S mutation in RPL10 . This specific mutation has been shown to drive IRES-dependent BCL-2 translation and amplify JAK-STAT signaling, two processes that are critical in leukemia development and progression .

These findings suggest that RPL10, especially through its extra-ribosomal functions, may play important roles in different types of tumorigenesis beyond pancreatic cancer . The identification of specific mutations like R98S provides potential targets for therapeutic intervention and diagnostic markers in hematological malignancies. Further research into how RPL10 mutations and modifications affect different cancer types may yield additional insights into cancer biology and potential treatment strategies.

How can RPL10 and RPL5 serve as diagnostic biomarkers for rhabdoid tumors?

Research has identified RPL10 and RPL5 as potential novel diagnostic biomarkers for rhabdoid tumors (RTs), particularly Atypical teratoid/rhabdoid tumors (AT/RTs) . These aggressive pediatric tumors often present diagnostic challenges due to their histological variability and overlapping features with other malignancies. Through molecular profiling approaches, researchers have found that RPL10 and RPL5 exhibit significant differential expression in AT/RT cases .

Analysis using Receiver Operating Characteristic methodology demonstrated that these ribosomal proteins show high sensitivity and specificity not only in the diagnosis of AT/RT but also in the differential diagnosis between AT/RT and Kidney Rhabdoid Tumors (KRT) . This finding is particularly valuable because current diagnostic approaches for RTs rely heavily on the lack of SMARCB1/INI1 protein expression, which accounts for only about 75% of RTs and is not exclusive to these tumors .

The identification of RPL10 and RPL5 as potential biomarkers represents a significant advancement in the molecular diagnosis of these challenging pediatric tumors. Their implementation in diagnostic panels could potentially improve diagnostic accuracy and help guide treatment decisions for patients with suspected rhabdoid tumors .

How should researchers address potential cross-reactivity with RPL10L when using RPL10 antibodies?

A significant challenge when working with RPL10 antibodies is the potential cross-reactivity with RPL10L, as these proteins share approximately 98% amino acid sequence identity . This high degree of similarity means that most commercially available RPL10 antibodies will recognize both proteins, potentially complicating data interpretation in experimental contexts where distinguishing between these proteins is critical.

To address this issue, researchers should consider several approaches:

• Genetic manipulation: Using siRNA or CRISPR-Cas9 to selectively knock down one protein can help determine the contribution of each to the observed signal.

• Mass spectrometry: For definitive protein identification, mass spectrometry can distinguish between RPL10 and RPL10L based on the few amino acid differences.

• Tissue-specific expression analysis: RPL10L shows more restricted expression patterns than RPL10, which can help interpret results in certain tissue contexts.

• Custom antibody development: For studies specifically focused on distinguishing these proteins, custom antibodies targeting the regions of difference may be necessary.

When publishing research involving RPL10 antibodies, it is advisable to acknowledge the potential cross-reactivity with RPL10L and describe any steps taken to address this limitation in experimental design and data interpretation.

What techniques are optimal for studying RPL10 post-translational modifications, particularly ufmylation?

Studying post-translational modifications of RPL10, especially ufmylation, requires specialized techniques to capture these often transient and substoichiometric modifications. Co-immunoprecipitation (Co-IP) has proven effective for detecting RPL10 ufmylation in both cell lines and clinical specimens . In this approach, cell or tissue lysates are subjected to immunoprecipitation with antibodies against either RPL10 or UFM1, followed by Western blotting with the complementary antibody to detect the modified protein .

For more detailed characterization of ufmylation sites, mass spectrometry-based proteomics approaches are recommended. These methods can identify specific lysine residues that undergo ufmylation and quantify the extent of modification at each site . Site-directed mutagenesis of identified ufmylation sites provides a powerful approach to assess the functional significance of these modifications, as demonstrated in studies of pancreatic cancer where mutation of ufmylation sites impeded cancer cell proliferation and stemness .

To study the enzymes involved in RPL10 ufmylation, approaches involving the overexpression or knockdown of UFL1 (the E3 ligase) and UFSP2 (the deufmylating enzyme) have provided valuable insights . When UFSP2 was overexpressed, for example, the level of RPL10 ufmylation was notably reduced, confirming its role in regulating this modification .

What methodological considerations are important when analyzing RPL10 expression across different microarray datasets?

Comparing RPL10 expression across different microarray platforms presents significant technical challenges due to platform-specific differences in probe design, hybridization conditions, and normalization methods. To address these challenges, researchers have successfully employed the Array Generation based gene Centering (AGC) method to make RPL10 expression data comparable across different datasets .

The AGC method scales datasets using a scaling factor defined based on housekeeping genes, providing a more reliable comparison across different array types . This approach was effectively used to compare RPL10 expression between datasets generated on Affymetrix Human Gene 1.1 ST Array and Affymetrix Human Genome U133A Array platforms .

When analyzing RPL10 expression in clinical samples, it's important to consider potential confounding factors such as tissue heterogeneity, patient demographics, treatment history, and sample collection methods. Incorporating appropriate statistical controls and validation in independent cohorts strengthens the reliability of findings related to RPL10 expression in disease contexts . Additionally, complementing microarray-based expression analysis with protein-level validation via techniques like Western blotting or immunohistochemistry provides more comprehensive characterization of RPL10 alterations in experimental or clinical samples.

What are common issues in Western Blot applications of RPL10 antibodies and how can they be resolved?

Western Blot applications with RPL10 antibodies may encounter several common issues that require specific troubleshooting approaches. One frequent challenge is distinguishing the RPL10 signal (25 kDa) from other similarly sized proteins or non-specific bands. This can be addressed through careful optimization of antibody dilution, with the recommended range of 1:1000 to 1:6000 serving as a starting point for titration . Using validated positive controls such as HeLa cells, COLO 320 cells, or brain tissue from mouse or rat can help establish the correct band pattern .

Another common issue is weak signal strength, which may be improved through several approaches:

• Increasing protein loading (though this may also increase background)

• Extending primary antibody incubation time (overnight at 4°C may yield better results than shorter incubations)

• Optimizing blocking conditions to reduce non-specific binding without compromising specific signal

• Using enhanced chemiluminescence (ECL) detection systems with appropriate sensitivity for the expected signal strength

Background issues can be addressed by increasing washing steps, optimizing blocking conditions, and ensuring the freshness of all reagents used in the protocol. When troubleshooting Western Blot applications, it's advisable to make one methodological change at a time to clearly identify which modification improves results.

What is the optimal experimental design for investigating RPL10's role in cancer cell stemness?

Investigating RPL10's role in cancer cell stemness requires a multifaceted experimental approach that addresses both molecular mechanisms and functional outcomes. Based on recent research implicating RPL10 ufmylation in pancreatic cancer stemness , an optimal experimental design would include:

• Molecular characterization:

  • Analysis of RPL10 expression and ufmylation status in cancer stem cells versus bulk tumor cells

  • Investigation of correlation between RPL10 ufmylation and established stemness markers

  • Assessment of transcription factors like KLF4 that link RPL10 modification to stemness phenotypes

• Functional assays:

  • Sphere formation assays to evaluate self-renewal capacity

  • Limiting dilution assays to quantify tumor-initiating cell frequency

  • Lineage tracing to assess differentiation potential

  • Resistance to conventional therapies, a hallmark of cancer stem cells

• Genetic manipulation strategies:

  • CRISPR-Cas9 mediated mutation of RPL10 ufmylation sites

  • Modulation of ufmylation machinery (UFL1 and UFSP2) expression

  • Rescue experiments to confirm specificity of observed phenotypes

• In vivo validation:

  • Xenograft models to assess tumor-initiating capacity

  • Patient-derived xenografts to validate findings in clinically relevant models

  • Correlation of RPL10 ufmylation with patient outcomes and therapy response

This comprehensive approach allows for both mechanistic understanding of RPL10's role in stemness and validation of its potential as a therapeutic target in cancer treatment strategies.